Skip to main content
. 2021 Apr 11;10(8):1621. doi: 10.3390/jcm10081621

Figure 2.

Figure 2

Serum PCSK9 in patients with chronic HCV stratified for steatosis, fibrosis scores and cirrhosis. (A) PCSK9 in serum of 37 patients with and 45 patients without liver steatosis; serum PCSK9 levels in patients stratified for fibrosis by (B) the acoustic radiation force impulse (ARFI) score; (C) the fibrosis-4 (FIB-4) score; (D) the non-alcoholic fatty liver disease (NAFLD) score and (E) the aminotransferase/platelet ratio index (APRI) score (no fibrosis = no; not reliable values = NR, fibrosis = yes); (F) serum PCSK9 in 37 patients with liver cirrhosis and 45 non-cirrhotic patients assessed by ultrasound. Small circles above or below the boxes mark outliers. * p < 0.05, ** p < 0.01, *** p < 0.001.